Heidelberg Pharma announces financial figures and reports on successful business performance in 2023 : vimarsana.com

First efficacy data from the clinical trial with HDP-101 in multiple myelomaExpansion of the ADC technology platform to include further payloadsNew Management Board teamSuccessful financing activities; sales revenue and other income above planConference call to be held on 25 March 2024 at 03:00 pm CET/ 10:00 am EDT&...

Related Keywords

Hangzhou , Zhejiang , China , Huadong , Guangdong , Australia , Germany , Binghamton , New York , United States , Delaware , Indiana , Cambridge , Cambridgeshire , United Kingdom , Melbourne , Victoria , American , Andreas Pahl , Walter Miller , Eli Lilly , Heidelberg Pharma , Jan Schmidt , Drug Administration , American Association For Cancer Research , Heidelberg Pharma Research , Binghamton University , Huadong Medicine Co Ltd , European Patent Office , Good Laboratory Practice , University Of New York , Telix Pharmaceuticals , Heidelberg Pharma Group , Heidelberg Pharma Research Gmb , Management Board , Annual Report , Chief Executive Officer , Chief Financial Officer , American Association , Cancer Research , Annual Meeting , Heidelberg Pharma Research Gmbh , New Management Board , Chief Financial , Managing Director , Jan Schmidt Brand , Supervisory Board , Professor Andreas Pahl , Emergence Therapeutics , State University , Magenta Therapeutics , Partner Takeda Oncology , Telix Pharmaceuticals Limited , Biologics License Application , Healthcare Royalty , Executive Board ,